Vaxart's Booster Study Of Oral Norovirus Vaccine Yields Encouraging Immune Responses

Shares of Vaxart Inc. (VXRT) are up more than 11% at $9.12 in pre-market trading Thursday, following encouraging news from the company's first booster clinical study of its oral norovirus vaccine.

Study Results

In a 12-subject phase Ib, the participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021.

All seven participants who had been?previously immunized with the oral norovirus vaccine elicited?a?similar?broad range of?immune responses?to norovirus as the five subjects that had not received a prior oral vaccine dose.??

When viral vector-based vaccines are injected, they generate immune responses against the viral vector as well as the intended antigens. However, Vaxart's vaccines may not be hampered by certain antibody response challenges that can occur with injectable viral vector-based vaccines, the company added.

Potential Implications

Since the company's other oral vaccine tablets are also based on the same platform as that of the oral norovirus vaccine and use the same vector, the findings have potential implications for the COVID-19 oral vaccine program, said Andrei Floroiu, Vaxart's Chief Executive Officer.

The company's oral tablet COVID-19 vaccine candidate, VXA-CoV2-1, is expected to advance into a Phase II trial.

VXRT has traded in a range of $3.50 to $24.90 in the last 1 year. The stock closed yesterday's trading at $8.21, up 2.24%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT